Therapeutic antibodies have transformed modern biopharmaceuticals, providing targeted and highly specific treatments for a range of diseases, including oncology, autoimmune disorders, and infectious diseases.
However, immunogenicity concerns, particularly the development of anti-drug antibodies (ADAs), continue to pose challenges, affecting the pharmacokinetics (PK), efficacy and safety profiles of these biologics.
In this post, we delve into the key insights from a recent editorial in Frontiers in Immunology on the immune response to therapeutic antibodies and explore how Svar Life Science can help overcome these challenges.